1.
Cost‑effectiveness analysis of apixaban versus other NOACs for the prevention of stroke in Italian atrial fibrillation patients. FE [Internet]. 2014 Dec. 22 [cited 2026 Feb. 15];15(4):101-12. Available from: https://journals.seedstm.com/index.php/FE/article/view/971